글로벌 암 진단 시장 규모, 점유율 및 추세 분석 보고서 – 산업 개요 및 2031년까지의 예측

암 진단 시장 분석

암 진단 시장은 전 세계적으로 암 유병률이 증가하고 조기 발견 및 개인화된 치료에 대한 수요가 증가함에 따라 상당한 성장을 경험하고 있습니다. 영상 기술, 바이오마커 식별 및 유전자 검사를 포함한 진단 기술의 발전으로 암 진단의 정확도와 속도가 향상되고 있습니다. 주요 업체는 진단 기능을 향상시키기 위해 연구 개발에 많은 투자를 하고 있으며, 다양한 유형의 암에 맞는 혁신적인 솔루션으로 이어지고 있습니다. 진단 프로세스에 인공 지능을 통합하는 것과 같은 최근의 발전은 워크플로를 간소화하고 임상 환경 에서 의사 결정을 향상시키고 있습니다 . 예방 의료로의 전환과 개인화된 의학에 대한 강조가 커지면서 의료 서비스 제공자는 개별 환자 프로필에 따라 맞춤형 치료 계획을 제공하고자 하기 때문에 시장이 더욱 촉진되고 있습니다. 전반적으로 암 진단 시장은 기술 발전과 조기 개입에 대한 집중 증가로 인해 지속적인 확장을 앞두고 있습니다.

암 진단 시장 규모

글로벌 암 진단 시장 규모는 2023년에 1,798만 달러로 평가되었으며, 2031년까지 3,255만 달러에 도달할 것으로 예상되며, 2024년에서 2031년까지의 예측 기간 동안 CAGR은 7.70%입니다. Data Bridge Market Research에서 큐레이팅한 시장 보고서에는 시장 가치, 성장률, 세분화, 지리적 범위, 주요 업체와 같은 시장 시나리오에 대한 통찰력 외에도 심층 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크도 포함됩니다.

암 진단 시장 동향

“조기 발견 및 치료 의 혁신 ”

The cancer diagnostics market is evolving rapidly, driven by innovations aimed at improving detection and treatment. One significant trend is the integration of artificial intelligence (AI) into diagnostic processes, which enhances the accuracy of imaging and analysis, enabling earlier detection of various cancers. AI algorithms can analyze vast amounts of data, identify patterns, and assist healthcare professionals in making more informed decisions. In addition, advancements in liquid biopsy technology are transforming how cancers are diagnosed, allowing for non-invasive testing that provides insights into tumor characteristics and treatment response. Overall, these innovations are revolutionizing cancer diagnostics, leading to improved patient outcomes and more personalized treatment approaches, ultimately reshaping the landscape of oncology care.

Report Scope and Cancer Diagnostics Market Segmentation 

Cancer Diagnostics Market Definition

Cancer diagnostics encompasses a range of tests and procedures designed to detect, identify, and characterize cancer. This includes imaging techniques such as X-rays, CT scans, and MRIs, as well as laboratory tests like blood tests and biopsies. Molecular diagnostics, which analyze genetic mutations related to cancer, are also an integral part of the diagnostic process. Effective cancer diagnostics enable early detection and accurate staging, allowing for personalized treatment plans tailored to the specific type and characteristics of the cancer.

Cancer Diagnostics Market Dynamics

Drivers

• Rising Incidence of Cancer Diagnostics

The rising prevalence of cancer globally is a significant driver of demand for diagnostic tests, as the disease affects millions of individuals each year. Factors such as an aging population, where older adults are more susceptible to various cancers, contribute to this trend. In addition, lifestyle changes, including poor diet, lack of physical activity, and increased tobacco and alcohol use, have led to higher cancer rates. Environmental factors, such as exposure to pollutants and hazardous substances, further exacerbate the situation, increasing the risk of developing cancer. As a result, healthcare providers and patients alike are prioritizing early detection and diagnosis, making effective cancer diagnostics essential. The growing focus on timely and accurate cancer detection underscores the importance of innovative diagnostic tests, thereby driving growth in the cancer diagnostics market.

• Advancements in Diagnostic Technologies

Innovations in diagnostic technologies have significantly enhanced the accuracy and efficiency of cancer detection, driving growth in the cancer diagnostics market. Liquid biopsies, for instance, allow for the non-invasive detection of cancer biomarkers in bodily fluids, providing crucial information about tumor dynamics and treatment response. Similarly, molecular diagnostics have revolutionized the identification of specific genetic mutations and alterations associated with various cancers, enabling personalized treatment approaches. Advanced imaging techniques, such as MRI and PET scans, offer high-resolution visuals of tumors, aiding in precise localization and staging. These technological advancements improve the overall accuracy of diagnoses and facilitate earlier intervention, leading to better patient outcomes. The continuous evolution of these innovative diagnostic tools is fostering market growth and transforming cancer care.

Opportunities

• Increasing Personalized Medicine

The increasing shift toward personalized medicine is reshaping the landscape of cancer diagnostics, generating substantial demand for specific tests that can accurately identify suitable therapies based on individual genetic profiles. As healthcare moves away from one-size-fits-all treatments, there is a growing recognition of the importance of understanding a patient’s unique genetic makeup to determine the most effective therapeutic strategies. This trend has prompted diagnostic companies to develop advanced tests, such as companion diagnostics, which facilitate the identification of biomarkers and guide treatment decisions for targeted therapies. By enabling healthcare providers to customize treatment plans tailored to each patient's needs, this personalized approach enhances therapeutic outcomes and minimizes adverse effects, ultimately driving the growth of the cancer diagnostics market as healthcare systems increasingly prioritize precision medicine.

• Artificial Intelligence (AI) and Machine Learning

The integration of advanced technologies, such as artificial intelligence (AI) and machine learning, is revolutionizing the field of cancer diagnostics, creating significant market opportunities. These technologies enhance the accuracy of cancer detection and diagnosis by enabling faster and more precise analysis of complex datasets, including medical imaging and genomic information. AI algorithms can identify patterns and anomalies that may be overlooked by human observers, leading to earlier and more reliable diagnoses. Furthermore, machine learning models can continuously improve their performance by learning from new data, thus refining diagnostic processes over time. As healthcare systems increasingly adopt these innovative technologies, they enhance diagnostic efficiency and improve patient outcomes, driving growth in the cancer diagnostics market. This trend highlights the potential for companies that leverage AI and machine learning to develop cutting-edge diagnostic solutions.

Restraints/Challenges

• High Costs of Advanced Diagnostic Technologies

The high costs associated with advanced diagnostic technologies pose a significant challenge in the cancer diagnostics market. Cutting-edge diagnostic tools, including molecular tests and imaging technologies, often come with substantial price tags, making them less accessible for healthcare facilities, particularly in low-resource settings. This financial barrier limits the ability of these institutions to offer comprehensive cancer screening and diagnostic services, ultimately affecting patient outcomes. In addition, the expenses incurred during research, development, and the regulatory approval process for new diagnostic tools further compound these financial challenges. Companies must invest considerable resources to meet stringent regulatory standards, which can delay the availability of innovative solutions and restrict market entry for smaller players, hindering overall progress in cancer diagnostics.

• Market Competition in Cancer Diagnostics

Intense competition among established players in the cancer diagnostics market creates a challenging environment that can adversely affect innovation and profitability. As companies strive to capture market share, aggressive pricing strategies often result in price wars, leading to squeezed profit margins. This relentless focus on competitive pricing can divert resources away from research and development, ultimately stifling innovation in the sector. Furthermore, the pressure to maintain low prices may discourage investment in new technologies, as companies may hesitate to allocate funds to innovative solutions that could take years to yield returns. Consequently, this competitive landscape may hinder the introduction of groundbreaking diagnostic tools, limiting advancements in cancer detection and management that are crucial for improving patient outcomes.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Cancer Diagnostics Market Scope

The market is segmented based on product, type, technology, application, and end user. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product

• Consumables
  • Antibodies
  • Kits & Reagents
  • Probes
  • Other Consumables
• Instruments
  • Pathology-based Instruments
  • Slide Staining Systems
  • Tissue Processing Systems
  • Cell Processors
  • PCR Instruments
  • NGS Instruments
  • Microarrays
  • Other Pathology-based Instruments

Technology

• IVD Testing
  • Polymerase Chain Reaction (PCR) • In Situ Hybridization (ISH)
  • Immunohistochemistry (IHC)
  • Next-generation Sequencing (NGS) • Microarrays
  • Flow Cytometry
  • Immunoassays
  • Other IVD Testing Technologies
• Imaging
  • Magnetic Resonance Imaging (MRI)
  • Computed Tomography (CT)
  • Positron Emission Tomography (PET)
  • Mammography
  • Ultrasound
• Biopsy Technique

Type

• Imaging Testing
• Biomarkers Testing
• In Vitro Diagnostic Testing
• Biopsy
• Others

Application

• Lung Cancer
• Breast Cancer
• Colorectal Cancer
• Melanoma Cancer
• Prostate Cancer
• Liver Cancer
• Others

End User

• Diagnostic Centres
• Hospitals and Clinics
• Research Institutes
• Others

Cancer Diagnostics Market Regional Analysis

The market is analysed and market size insights and trends are provided by country, product, type, application, technology, and end user as referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America leads the market primarily due to a robust presence of numerous biotechnology and medical device companies. The region benefits from significant funding directed toward research and development initiatives, fostering innovation and growth. In addition, the high adoption rate of advanced technologies further solidifies North America's dominance in the biotechnology sector.

Asia Pacific region is anticipated to experience significant growth in the market, driven by the highest number of registered clinical trials related to various therapies. Moreover, substantial government investments and reforms are expected to further enhance the development of chimeric antigen receptor (CAR)-T cell therapy in the region. This combination of factors positions Asia Pacific for a promising expansion in the coming years.

보고서의 국가 섹션은 또한 개별 시장 영향 요인과 국내 시장의 현재 및 미래 트렌드에 영향을 미치는 규제 변화를 제공합니다. 다운스트림 및 업스트림 가치 사슬 분석, 기술 트렌드 및 포터의 5가지 힘 분석, 사례 연구와 같은 데이터 포인트는 개별 국가의 시장 시나리오를 예측하는 데 사용되는 몇 가지 포인터입니다. 또한 글로벌 브랜드의 존재 및 가용성과 지역 및 국내 브랜드와의 대규모 또는 희소한 경쟁으로 인해 직면한 과제, 국내 관세 및 무역 경로의 영향이 국가 데이터에 대한 예측 분석을 제공하는 동안 고려됩니다.  

암 진단 시장 점유율

시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 포함된 세부 정보는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 글로벌 입지, 생산 현장 및 시설, 생산 용량, 회사의 강점과 약점, 제품 출시, 제품 폭과 범위, 애플리케이션 우세입니다. 위에 제공된 데이터 포인트는 시장과 관련된 회사의 초점에만 관련이 있습니다.

시장에서 운영되는 암 진단 시장 리더는 다음과 같습니다.

• 애벗(미국)
• 디아고(캐나다)
• Thermo Fisher Scientific(미국)
• 일루미나 주식회사(미국)
• QIAGEN(독일)
• F. 호프만-라 로슈 유한회사(스위스)
• Agilent Technologies, Inc. (미국)
• Quest Diagnostics Incorporated(미국)
• 머크 KGaA(독일)
• 홀로직 주식회사(미국)
• BD(미국)
• GSK plc (영국)
• 노바티스 AG(스위스)
• 브리스톨-마이어스 스퀴브 회사(미국)
• 엘리 릴리 앤드 컴퍼니(미국)
• 파이저 주식회사(미국)
• Exact Sciences Corporation(미국)
• 비오메리유(프랑스)
• 아스텔라스파마 주식회사(일본)
• Myriad Genetics, Inc. (미국)

암 진단 시장의 최신 동향

• 2024년 7월, DELFI Diagnostics는 Merck Global Health Innovation Fund로부터 지분 투자를 확보했다고 밝혔습니다. 이 자금은 암 검진을 위한 DELFI의 AI 기반 프래그멘토믹스 플랫폼 개발을 촉진하는 데 사용될 예정입니다. 이 협업은 진단 역량을 강화하고 암 탐지 방법론을 개선하는 것을 목표로 합니다.
• 2024년 5월 Quest Diagnostics는 인공지능 통합에 대한 집중을 강화하기 위해 PathAI의 디지털 병리학 실험실을 분리한다고 발표했습니다. 이 전략적 움직임은 운영 내에서 AI 기술 도입을 가속화하는 것을 목표로 합니다. 이 이니셔티브는 Quest Diagnostics의 디지털 병리학 역량을 강화하고 진단 정확도를 개선할 것으로 예상됩니다.
• 2023년 2월, F. Hoffmann-La Roche는 개인화된 의료 이니셔티브를 강화하기 위해 Janssen과의 협력을 확대한다고 발표했습니다. 이 파트너십은 환자의 치료 결과를 개선하는 것을 목표로 하는 동반 진단법의 개발을 강조할 것입니다. 확대된 협력은 두 회사가 의료 분야에서 맞춤형 치료 접근 방식을 발전시키려는 의지를 반영합니다.
• 2023년 11월, Abbott은 Alinity m 플랫폼에서 사용하도록 설계된 HPV 검사에 대한 FDA 승인을 받았습니다. 이 검사는 HPV에 대한 1차 스크리닝을 가능하게 하고 암과 관련된 고위험 유형을 식별합니다. 이 승인은 자궁경부암 예방 및 진단 분야에서 Abbott의 제공을 강화합니다.
• 2022년 Precipio, Inc.는 미국 내 주요 유통 파트너와 HemeScreen 제품에 대한 유통 계약을 체결했습니다. 이 회사는 의사 소유 실험실, 국가 및 지역 병원 네트워크, 참조 실험실에 초점을 맞춰 HemeScreen에 대한 포괄적인 확장 전략을 적극적으로 추진하고 있습니다. 이 다각적인 접근 방식은 다양한 의료 환경에서 HemeScreen의 도달 범위와 가용성을 향상시키는 것을 목표로 합니다.

SKU-1604